Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vadadustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 known ✓ | Q9GZT9 | 19/20 | 1.00 |
| ▸ | EGLN3 known ✓ | Q9H6Z9 | 8/20 | 1.00 |
| ▸ | FLT1 | P17948 | 7/20 | 1.00 |
| ▸ | VEGFA | P15692 | 6/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | KDM8 | Q8N371 | 1/20 | 1.00 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadadustat SCHEMBL29405970 | 1.00 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| Vadadustat SCHEMBL29357486 | 1.00 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFATET3 | |
| Vadadustat SCHEMBL1921291 | 0.94 | EGLN1 (0.89) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL14308517 | 0.91 | EGLN1 (0.83) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL21390798 | 0.90 | EGLN1 (0.82) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL16728915 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL1921390 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL15164149 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL30239851 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 | |
| SCHEMBL23501769 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3FLT1VEGFATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569474-B2 | Compositions and methods for treating anemia | AKEBIA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20240335434-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS, INC. | 2024-10-10 | — | — | US | claimed |
| US-20240325360-A1 | THERAPEUTIC METHODS USING VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | US | claimed |
| US-20240325361-A1 | Compositions and Methods for Treating Anemia | KREOS CAPITAL VII (UK) LIMITED (GB) | 2024-10-03 | — | — | US | claimed |
| US-20240148707-A1 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | claimed |
| EP-4360706-A2 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | Akebia Therapeutics Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117843565-A | Preparation method and application of pyridine compound | 南京正荣医药化学有限公司 | 2024-04-09 | — | — | CN | claimed |
| EP-3007695-B1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4301352-A1 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | Akebia Therapeutics Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| US-11857543-B2 | Compositions and methods for treating anemia | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-8940773-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | claimed |
| WO-2014200773-A2 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | AKEBIA THERAPEUTICS , INC. (US) | 2014-12-18 | — | — | WO | claimed |
| US-20140045899-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-8323671-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | claimed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569474-B2 | Compositions and methods for treating anemia | HIF1AN, HIF1A, EGLN2 | EGLN1 8/4885EGLN3 5/4885FLT1 567/4885 |
| US-20240325361-A1 | Compositions and Methods for Treating Anemia | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885EGLN3 3/4885FLT1 335/4885 |
| US-20240325360-A1 | THERAPEUTIC METHODS USING VADADUSTAT | EPOR, HAMP, HBG1 | EGLN1 26/4885EGLN3 25/4885FLT1 42/4885 |
| US-20240148707-A1 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | SLC34A1, ABCB1, SLC34A3 | EGLN1 3764/4885EGLN3 3130/4885FLT1 702/4885 |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20140045899-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885FLT1 55/4885 |
| US-20240335434-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA | HIF1AN, EGLN3, EGLN2 | EGLN1 5/4885EGLN3 2/4885FLT1 318/4885 |
| US-11857543-B2 | Compositions and methods for treating anemia | HIF1AN, EGLN3, EGLN2 | EGLN1 5/4885EGLN3 2/4885FLT1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.